Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2, 24

Antidepressants and Inflammatory Bowel Disease: A Systematic Review


Antidepressants and Inflammatory Bowel Disease: A Systematic Review

Antonina A Mikocka-Walus et al. Clin Pract Epidemiol Ment Health.


Background: A number of studies have suggested a link between the patient's psyche and the course of inflammatory bowel disease (IBD). Although pharmacotherapy with antidepressants has not been widely explored, some investigators have proposed that treating psychological co-morbidities with antidepressants may help to control disease activity. To date a systematic analysis of the available studies assessing the efficacy of antidepressants for the control of somatic symptoms in IBD patients has not been performed.

Methods: We searched electronic databases, without any language restriction. All relevant papers issued after 1990 were examined.

Results: 12 relevant publications were identified. All of them referred to non-randomised studies. Antidepressants reported in these publications included paroxetine, bupropion, amitriptyline, phenelzine, and mirtazapine. In 10 articles, paroxetine, bupropion, and phenelzine were suggested to be effective for treating both psychological and somatic symptoms in patients suffering from IBD. Amitriptyline was found ineffective for treating somatic symptoms of IBD. Mirtazapine was not recommended for IBD patients.

Conclusion: Although most of reviewed papers suggest a beneficial effect of treatment with antidepressants in patients with IBD, due to the lack of reliable data, it is impossible to judge the efficacy of antidepressants in IBD. Properly designed trials are justified and needed based upon the available uncontrolled data.

Similar articles

See all similar articles

Cited by 38 PubMed Central articles

See all "Cited by" articles


    1. Fort MM, Mozaffarian A, Stover AG, Correia Jda S, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefeldt-Ohmann H, Probst P, Jeffery E, Fling SP, Hershberg RM. A Synthetic TLR4 Antagonist Has Anti-Inflammatory Effects in Two Murine Models of Inflammatory Bowel Disease. J Immunol. 2005;174:6416–6423. - PubMed
    1. Macfarlane S, Furrie E, Kennedy A, Cummings JH, Macfarlane GT. Mucosal bacteria in ulcerative colitis. Br J Nutr. 2005;93 Suppl 1:S67–72. doi: 10.1079/BJN20041347. - DOI - PubMed
    1. Plevy S. A STAT need for human immunologic studies to understand inflammatory bowel disease. Am J Gastroenterol. 2005;100:73–74. doi: 10.1111/j.1572-0241.2005.41382.x. - DOI - PubMed
    1. Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004;53:1479–1484. doi: 10.1136/gut.2003.024828. - DOI - PMC - PubMed
    1. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scan J Gastroenterol. 1997;32:1013–1021. - PubMed

LinkOut - more resources